The approach to HIV treatment initiation has shifted dramatically from deliberate delays to rapid antiretroviral therapy (ART) start, driven by evidence demonstrating clinical and public health benefits.1 Same-day or next-day ART initiation represents standard practice for most newly diagnosed patients, yet successful implementation requires careful attention to patient readiness, regimen selection, and support systems.2
International guidelines now emphasize that treatment should begin as soon as possible after diagnosis due to demonstrable benefits in improving viral suppression, retention in care, long-term health outcomes, and survival.1-3 These recommendations reflect growing evidence that rapid ART initiation confers individual and population-level benefits, reinforcing its role as a cornerstone of contemporary HIV management. Reducing time between diagnosis and treatment start can prevent progressive immune system deterioration, decrease risk of opportunistic infections and hospitalizations, and reduce HIV transmission during the critical viremic phase following diagnosis.
Recent exploration of economic modeling demonstrates that doubling rapid start ART rates among newly diagnosed individuals may prevent approximately 7 HIV transmissions per 1000 people over three years, translating to one transmission prevented for every 141 individuals receiving rapid start.1 Although increasing rapid start ART results in higher initial treatment costs, these are offset by savings from reduced healthcare utilization associated with preserved CD4 counts and substantial lifetime cost savings from averted HIV infections, yielding a benefit-cost ratio of 10.5.1
Regimen selection at treatment initiation profoundly influences long-term outcomes. Integrase strand transfer inhibitor-based three-drug combinations remain preferred due to rapid virologic suppression, high genetic barrier to resistance, and favorable tolerability.3 Fixed-dose combinations containing bictegravir with emtricitabine and tenofovir alafenamide offer once-daily dosing without food requirements.3
However, rapid initiation does not mean forgoing clinical assessment. While ART should be started promptly without waiting for test results, providers must still order baseline resistance testing, renal and hepatic function studies, and assess for comorbidities, potential drug interactions, and barriers to medication adherence, recognizing that initial regimens may require adjustment once results are available.4,5 Patient-centered communication remains paramount. Discussing treatment goals, addressing concerns about side effects, and emphasizing the importance of adherence establishes a foundation for long-term partnership in care.6,7
By combining evidence-based rapid initiation strategies with individualized assessment and comprehensive support, clinicians can optimize early treatment outcomes and establish trajectories toward durable viral suppression.
Take our HIV quiz to see how your knowledge compares to your peers.
